6533b7d6fe1ef96bd12665db
RESEARCH PRODUCT
A review of venous thromboembolism in COVID‐19: A clinical perspective
Ersin GunaySavas OzsuStavros Konstantinidessubject
Pulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsCritical IllnessGlobal Health03 medical and health sciences0302 clinical medicineCOVID‐19medicineHumansImmunology and AllergyGenetics(clinical)030212 general & internal medicineanticoagulationIntensive care medicinePandemicsContraindicationGenetics (clinical)Critical perspectiveSARS-CoV-2business.industryCritically illIncidenceCOVID-19Venous ThromboembolismOriginal Articlesmedicine.diseasemortalityLMWHVenous thrombosis030228 respiratory systemOriginal Articlevenous thrombosisbusinessVenous thromboembolismThrombotic complicationdescription
Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalized COVID‐19 patients should take pharmacological thromboprophylaxis if there is no contraindication. However, there is no consensus on this issue. In this review, we discussed all these approaches in a critical perspective.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-05 | The Clinical Respiratory Journal |